We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : AMDL Inc.

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: paul lin who wrote (6)6/19/1996 2:31:00 PM
From: Chris Forte   of 28
Paul, the as far as I know, the DR-70 test has little competition in lung cancer. In other cancers it may bump up against other markers. Clinical trials in Germany are wrapping up now which was designed to test DR-70's effectiveness in diagnosing other cancers, which would give it some kind of ranking so to speak against other markers.
Your question is a good one - it's probably the whole key to this product - is it good enough for a doctor in the field to order it? I was initially concerned about the sensitivity also, but at the risk of sounding like a spin doctor(pardon the pun), it has to be taken in relation to what else is out there. Tests of this nature aren't 100%. Almost nothing is. Is it good enough to be clinically useful? In my opinion it is based on conversations I've
had with people a lot smarter than I am about these tests.
Remember also, one of the strong selling points of DR-70 is its ability to diagnose many types of cancer, and to act as a screening test for pre or post diagnostic uses. Will it be a "pan" tumor marker for all cancers? No. But is it a useful product for a clinician in multiple markets? I believe and hope so. Only time will tell. That's what's exciting to me... the time is coming soon. Chris
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext